Invivyd Announced Additional Initial Data From Its Ongoing Phase 1 Healthy Volunteer Clinical Trial Of Monoclonal Antibody Candidate, VYD222 For The Prevention Of Symptomatic Covid-19 In Immunocompromised People
Portfolio Pulse from Benzinga Newsdesk
Invivyd has announced additional initial data from its ongoing Phase 1 clinical trial of monoclonal antibody candidate, VYD222, for the prevention of symptomatic Covid-19 in immunocompromised people.
July 17, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Invivyd's ongoing Phase 1 trial of VYD222, a monoclonal antibody candidate for preventing symptomatic Covid-19 in immunocompromised people, has new data.
The announcement of new data from a Phase 1 trial is a significant development for Invivyd. If the data is positive, it could lead to further trials and potentially regulatory approval, which would be a major boost for the company. This could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100